Weight management has acquired quite a collection of injections over the past few years. Now, there is a new tablet at the table.
The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Foundayo, also known as orforglipron, for weight management and type 2 diabetes in the UK. This makes the UK the first country in Europe to approve this particular GLP-1 tablet.
For anyone whose relationship with needles is best described as "not ideal", that may sound like significant news. However, approval does not mean Foundayo is suitable for everyone or immediately available through the NHS.
Here is what the announcement actually means.
Table of Contents
2. How does orforglipron work?
3. Who has Foundayo been approved for?
5. What are the common side effects?
6. Is Foundayo available through the NHS?
7. Is Foundayo the UK's first weight-loss pill?
8. Will tablets replace weight-loss injections?
9. What does Foundayo's UK approval mean?
10. Sources
What is Foundayo?
Foundayo is the brand name for orforglipron, a prescription-only GLP-1 receptor agonist made by Eli Lilly. Unlike injectable GLP-1 treatments, it is taken as a tablet once a day. It has been authorised for weight loss and weight maintenance in eligible adults, alongside a reduced-calorie diet and increased physical activity. It has also been approved to help improve blood sugar control in adults with insufficiently controlled type 2 diabetes.
So yes, it is a weight-management treatment in tablet form. But swapping an injection for a tablet does not remove the need for a proper clinical assessment.
How does orforglipron work?
GLP-1 is a hormone the body naturally releases after eating. It plays a role in regulating appetite and blood sugar. Orforglipron acts on GLP-1 receptors, including in areas of the brain involved in appetite. This can help people feel fuller for longer, reduce hunger and experience fewer food cravings. In people with type 2 diabetes, it can also help lower blood sugar when levels are high.
The tablet may make eating less feel more manageable, but it does not make food, movement and wider health habits irrelevant. It is part of the plan, not the whole picture.
Who has Foundayo been approved for?
For weight management, Foundayo has been authorised for adults with:
- a body mass index (BMI) of 30 or above; or
- a BMI from 27 to below 30 and at least one weight-related health condition.
Meeting these criteria does not automatically mean the treatment is suitable for you. A prescriber will also consider your medical history, current medicines, general health and individual circumstances.
How is Foundayo taken?
Foundayo is taken once a day and can be taken at any time, with no food or water restrictions. That flexibility may appeal to people interested in an oral GLP-1 treatment. Some tablets, including Wegovy tablets by Novo Nordisk, have more specific instructions about fasting, food and even the amount of water you have to drink. According to the MHRA, Foundayo does not have these restrictions.
Treatment begins at a low dose and increases gradually, with at least one month at each dose level. Anyone prescribed Foundayo should follow their prescriber's instructions and read the Patient Information Leaflet.
What are the common side effects?
The most common side effects identified by the MHRA are mainly digestive. They include:
- nausea
- constipation
- diarrhoea
- vomiting
- indigestion
- abdominal pain
Anyone concerned about symptoms should speak to their doctor, pharmacist or nurse. Suspected side effects can also be reported through the MHRA Yellow Card scheme.
GLP-1 medicines have also been associated with a small risk of acute pancreatitis. Severe and persistent stomach pain, particularly if it spreads to the back or occurs with nausea or vomiting, requires urgent medical attention.
Is Foundayo available through the NHS?
It's not currently available for weight management. MHRA authorisation confirms that Foundayo has met the regulator's standards for quality, safety and effectiveness. It does not automatically mean the treatment will be routinely funded by the NHS.
The National Institute for Health and Care Excellence (NICE) will need to assess its clinical evidence and cost-effectiveness before making recommendations. In other words, "approved in the UK" and "available through the NHS" are not interchangeable.
Private availability may also depend on the product's launch date, stock and individual pharmacy services.
Is Foundayo the UK's first weight-loss pill?
No, and this distinction matters. The MHRA approved a tablet form of Wegovy for weight management in June 2026. Foundayo's personal milestone is that the UK is the first country in Europe to authorise orforglipron, this particular GLP-1 tablet.
Headlines usually enjoy a dramatic entrance. The small print, like right here, is usually where the useful information lives.
Will tablets replace weight-loss injections?
Not necessarily, since a daily tablet may suit people who dislike needles or find oral medication easier to fit into their routine. Others may prefer a weekly treatment or be better suited to a different option.
Convenience is only part of the decision. Effectiveness, side effects, medical history, current medicines and personal preferences all need to be considered. Foundayo does not create one universal "best" treatment. It adds another potential option for patients who have either tried everything, are looking to switch, or are just starting out.
What does Foundayo's UK approval mean?
It means a new once-daily GLP-1 tablet has been approved in the UK for weight management and type 2 diabetes.
For eligible adults who would prefer an oral treatment, Foundayo could eventually provide another choice. However, it will not be suitable for everyone, side effects are possible and treatment decisions must be made with a qualified healthcare professional.
The real news, in summary, is that a new type of GLP-1 treatment has been approved, potentially giving patients better options and prescribers a wider scope to support your weight loss journey the right way.
Sources
- MHRA: UK first in Europe to authorise orforglipron for weight management and type 2 diabetes
- NICE: Orforglipron for managing overweight and obesity
- NICE: How NICE makes its decisions
- MHRA: First GLP-1 tablet for weight loss approved in the UK
- MHRA: Strengthened warnings about acute pancreatitis with GLP-1 medicines
- MHRA Yellow Card scheme
- MHRA Products: Patient Information Leaflets and medicine information
